WGS_OUT_1 [2025-04-14 10:33:37 -0400] 3588 Bytes | 954 tokens | Cum: 954 tkns (11.92% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and GeneDx (WGS) hit my radar screen, up to 101.8000 from a prev close of 96.6300 Do you think its got more juice or is it lacking potential? It's 10:33:37 AM on Mon Apr 14, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: GeneDx (WGS)
IPO: 2021-07-23 (3 Years Ago)
Market Cap: $2,712,237,317
Shares Outstanding: 28,070,000
Industry: SERVICES-HEALTH SERVICES
Exchange: XNAS
Description: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Here’s the first list of news for GeneDx:

C1 - Apr-08-25 08:05AM - GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025
C2 - Apr-03-25 08:00AM - GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
C3 - Apr-02-25 09:33AM - Buy 3 Momentum Anomaly Stocks as Markets Rise Despite Tariff Threats
C4 - Mar-22-25 05:48PM - Is GeneDx Holdings (WGS) The High Growth Low Debt Stock to Invest in Now?
C5 - Mar-20-25 04:05PM - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C6 - Mar-20-25 04:05PM 09:05AM - Invesco Health Care Fund Q4 2024 Commentary
C7 - Mar-19-25 05:00AM - Zacks.com featured highlights DRDGOLD, GeneDx, EverQuote, HCI Group and Alibaba
C8 - Mar-18-25 07:05AM - Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: GeneDx (WGS).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

WGS_OUT_3 [2025-04-14 10:33:38 -0400] 962 Bytes | 296 tokens | Cum: 1252 tkns (15.65% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-14T11:35:41Z - Next Century Growth Investors LLC Purchases 170,901 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)...
A2 - 2025-04-14T09:41:52Z - F M Investments LLC Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)...
A3 - 2025-04-14T07:32:16Z - Pictet Asset Management Holding SA Invests $222,000 in GeneDx Holdings Corp. (NASDAQ:WGS)...
A4 - 2025-04-14T07:20:35Z - LPL Financial LLC Acquires Shares of 35,621 GeneDx Holdings Corp. (NASDAQ:WGS)...
A5 - 2025-04-13T07:40:24Z - Vanguard Group Inc. Increases Stock Position in GeneDx Holdings Corp. (NASDAQ:WGS)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

WGS_OUT_5 [2025-04-14 10:33:43 -0400] 1098 Bytes | 310 tokens | Cum: 1564 tkns (19.55% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Next Century Growth Investors LLC Purchases 170,901 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)**Date: 2025-04-14Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/next-century-growth-investors-llc-purchases-170901-shares-of-genedx-holdings-corp-nasdaqwgs-2025-04-12/Next Century Growth Investors LLC boosted its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 121.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,014 shares of the company's stock after purchasing an additional 170,901 shares during the quarter. GeneDx makes up about 1.8% of Next Century Growth Investors LLC's investment portfolio, making the stock its 10th largest holding. Next Century Growth Investors LLC owned about 1.14%

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_7 [2025-04-14 10:33:45 -0400] 1098 Bytes | 283 tokens | Cum: 1942 tkns (24.27% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): of GeneDx worth $23,981,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in WGS. Sterling Capital Management LLC lifted its stake in GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares during the last quarter. F M Investments LLC acquired a new stake in shares of GeneDx in the 4th quarter worth about $574,000. Raymond James Financial Inc. bought a new stake in GeneDx in the 4th quarter valued at about $20,371,000. Renaissance Technologies LLC boosted its stake in GeneDx by 119.2% during the 4th quarter. Renaissance Technologies LLC now owns 205,116 shares of the company's stock valued at $15,765,000 after purchasing an additional 111,543 shares during the period. Finally, Legal & General Grou

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_9 [2025-04-14 10:33:45 -0400] 1098 Bytes | 289 tokens | Cum: 2263 tkns (28.29% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): p Plc grew its position in GeneDx by 31.1% in the 4th quarter. Legal & General Group Plc now owns 11,123 shares of the company's stock worth $855,000 after purchasing an additional 2,638 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

WGS has been the subject of several recent analyst reports. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_11 [2025-04-14 10:33:50 -0400] 1098 Bytes | 291 tokens | Cum: 2556 tkns (31.95% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): target price of $72.33.

Read Our Latest Report on GeneDx

In related news, CEO Katherine Stueland sold 46,594 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the completion of the transaction, the chief executive officer now directly owns 1,720 shares in the company, valued at $154,146.40. This represents a 96.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Feeley sold 15,516 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $92.18, for a total transaction of $1,430,264.88. Following the completion of the sale, the chief financial officer now owns 1,726 shares in the comp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_13 [2025-04-14 10:33:51 -0400] 1098 Bytes | 336 tokens | Cum: 2938 tkns (36.73% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): any, valued at $159,102.68. This represents a 89.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is owned by corporate insiders.

NASDAQ WGS opened at $96.63 on Friday. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1 year low of $8.63 and a 1 year high of $115.60. The company has a market cap of $2.71 billion, a PE ratio of -49.30 and a beta of 1.93. The stock's 50-day moving average price is $90.43 and its two-hundred day moving average price is $78.11.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. The b

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_15 [2025-04-14 10:33:52 -0400] 897 Bytes | 294 tokens | Cum: 3234 tkns (40.42% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-18T20:50:00Z - GeneDx Stock Was up 2,700% in 2024 — Can It Keep Rising?
B2 - 2024-11-16T09:54:00Z - Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
B3 - 2024-11-03T14:28:42Z - Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
B4 - 2024-07-19T23:12:47Z - Opko Health sells $823k of GeneDx holdings shares - Investing.com
B5 - 2024-07-17T17:01:29Z - Expert Ratings For GeneDx Hldgs - Benzinga
B6 - 2024-06-26T14:01:24Z - The Latest Analyst Ratings For GeneDx Hldgs

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

WGS_OUT_17 [2025-04-14 10:33:58 -0400] 733 Bytes | 220 tokens | Cum: 3456 tkns (43.20% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**GeneDx Stock Was up 2,700% in 2024 — Can It Keep Rising?**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/genedx-stock-was-up-2700-in-2024--can-it-keep-rising-200657485GeneDx, a leader in genome and exome testing, saw its stock price surge over 2,700% in 2024. The company's strong earnings and revenue growth in Q4 2024 have continued into 2025, with the stock price spiking 47% on Tuesday. However, a recent negative report by Grizzly Research has raised concerns about the company's growth.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_19 [2025-04-14 10:34:01 -0400] 804 Bytes | 197 tokens | Cum: 3850 tkns (48.12% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-02-20 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes appear...

S9 - 2025-02-18 8-K Item 2.02 Results of Oper and Fin Cond.

On February 18, 2025 , GeneDx Holdings Corp. (the Company) issued a press release (the Press Release) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2024 . Copie...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

WGS_OUT_21 [2025-04-14 10:34:02 -0400] 1098 Bytes | 220 tokens | Cum: 4072 tkns (50.90% of 8k)
==========================================================================

Showing S8 (chunk 1 of 6): S8:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements and involves numerous risks and uncertainties. Actual results may differ materially from the results described in or implied by the forward-looking statements. You should carefully read the section entitled Risk Factors to gain an understanding of the important factors that could cause actual results to differ materially from these forward-looking statements.

Overview

See Note 1, Organization and Description of Business included within this Annual Report for further information.

Factors Affecting Our Ope

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WGS_OUT_23 [2025-04-14 10:34:09 -0400] 14688 Bytes | 4015 tokens | Cum: 8089 tkns (101.11% of 8k)
==========================================================================

This is our set of metrics for {co_name}.
Please analyze the numbers.

+-------------------+------------------------+-------------------------+------------------------+
| Volume: 214,990 | Perf Month: 1.47% | Option/Short: Yes / Yes | Sales Y/Y TTM: 50.79% |
+-------------------+------------------------+-------------------------+------------------------+
| Avg Volume: 1.05M | Perf Quarter: 17.54% | Short Float: 11.28% | ROE: -22.10% |
+-------------------+------------------------+-------------------------+------------------------+
| Rel Volume: 1.23 | Index: RUT | Short Ratio: 2.64 | ROI: -14.60% |
+-------------------+------------------------+-------------------------+------------------------+
| RSI (14): 57.72 | Market Cap: 2.80B | Short Interest: 2.76M | Sales Surprise: 16.30% |
+-------------------+------------------------+-------------------------+------------------------+
| ATR (14): 8.92 | Shs Outstand: 28.02M | Beta: 1.92 | EPS Surprise: 372.67% |
+-------------------+------------------------+-------------------------+------------------------+
| SMA20: 7.94% | Shs Float: 24.47M | Sales Q/Q: 66.57% | P/E: - |
+-------------------+------------------------+-------------------------+------------------------+
| SMA50: 10.92% | Inst Own: 86.14% | Sales past 5Y: 16.51% | Earnings: Apr 30 BMO |
+-------------------+------------------------+-------------------------+------------------------+
| SMA200: 56.41% | Insider Own: 12.82% | Employees: 1000 | |
+-------------------+------------------------+-------------------------+------------------------+
| Perf Week: 17.87% | Insider Trans: -27.93% | Debt/Eq: 0.48 | |
+-------------------+------------------------+-------------------------+------------------------+

The next section covers any insider trading by {co_name} officers or majority shareholders (if available).

Inside Trans: GeneDx Holdings Corp. (WGS) by Stueland Katherine (Chief Executive Officer) on 2025-04-09
- Class A Common Stock: 2024 shares at $81.1573 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 3134 shares at $82.1661 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 3297 shares at $83.2532 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 2745 shares at $84.2798 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 3175 shares at $85.4369 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 5855 shares at $86.3448 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 373 shares at $87.3005 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 300 shares at $88.6967 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 1600 shares at $90.1296 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 1900 shares at $91.2737 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 1000 shares at $92.28 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 9628 shares at $93.3276 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 4511 shares at $94.5504 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 3173 shares at $95.5098 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 3174 shares at $96.2938 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- Class A Common Stock: 705 shares at $97.2443 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.

Inside Trans: GeneDx Holdings Corp. (WGS) by Feeley Kevin (CHIEF FINANCIAL OFFICER) on 2025-04-09
- Class A Common Stock: 1246 shares at $32.67 (D)
- Class A Common Stock: 637 shares at $83.6689 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 1198 shares at $84.6065 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 1171 shares at $85.7312 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 249 shares at $86.48 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 6810 shares at $93.2617 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 3122 shares at $94.598 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 1463 shares at $95.5287 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 846 shares at $96.4576 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Class A Common Stock: 20 shares at $97.26 (D) Footnote: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- Employee Stock Option (Right to Buy): 1246 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by Stueland Katherine (Chief Executive Officer) on 2025-03-26
- Class A Common Stock: 80000 shares at $0 (D)
- Class A Common Stock: 44801 shares at $95.6577 (D) Footnote: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to
cover" transaction
- Class A Common Stock: 1750 shares at $94.585 (D) Footnote: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to
cover" transaction
- Restricted Stock Unit: 80000 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by Feeley Kevin (CHIEF FINANCIAL OFFICER) on 2025-03-26
- Class A Common Stock: 16250 shares at $0 (D)
- Class A Common Stock: 8418 shares at $95.6577 (D) Footnote: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- Class A Common Stock: 328 shares at $94.4037 (D) Footnote: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- Restricted Stock Unit: 16250 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by Stueland Katherine (Chief Executive Officer) on 2025-03-09
- Class A Common Stock: 6546 shares at $0 (D)
- Class A Common Stock: 2731 shares at $94.7254 (D) Footnote: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to
cover" transaction
- Restricted Stock Unit: 6546 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by Feeley Kevin (CHIEF FINANCIAL OFFICER) on 2025-03-09
- Class A Common Stock: 2462 shares at $0 (D)
- Class A Common Stock: 922 shares at $94.7226 (D) Footnote: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- Restricted Stock Unit: 2462 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by Feeley Kevin (CHIEF FINANCIAL OFFICER) on 2025-03-01
- Class A Common Stock: 717 shares at $0 (D)
- Class A Common Stock: 261 shares at $103.94 (D) Footnote: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
- Restricted Stock Unit: 717 shares at $0 (D)

Inside Trans: GeneDx Holdings Corp. (WGS) by RUCH JOSHUA (Unknown Title) on 2025-02-05
- Class A Common Stock: 5816 shares at $7.89 (D)
- Stock Option (right to buy): 5816 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 305450000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -52286000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 101.8
Average Volume: 731747.95
30-Day High: 104.39
30-Day Low: 80.02

[Detailed Financials: TTM 2024]
- Total Assets: $419,380,000.0
- Total Liabilities: $174,133,000.0
- Total Equity: $245,247,000.0
- Current Assets: $197,968,000.0
- Current Liabilities: $54,817,000.0

[Income Statement: TTM 2024]
- Revenue: $305,450,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.94

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-14,466,000.0

[Detailed Financials: FY 2024]
- Total Assets: $419,380,000.0
- Total Liabilities: $174,133,000.0
- Total Equity: $245,247,000.0
- Current Assets: $197,968,000.0
- Current Liabilities: $54,817,000.0

[Income Statement: FY 2024]
- Revenue: $305,450,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.94

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-14,466,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of GeneDx (WGS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about GeneDx.

2) MARKET_SCORE[]
This conversation was initiated because WGS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for WGS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, WGS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect WGS to increase 50% from its current price of $101.80, say: PRICE_TARGET[152.7]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of GeneDx.

11) ETHICAL_RATING[]
Rate GeneDx’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

WGS_IN_25 [2025-04-14 10:34:10 -0400] 126 Bytes | 29 tokens | Cum: 8311 tkns (103.89% of 8k)
==========================================================================

====================================
[2025-04-14 10:34:10] # Analysis Completed
Elapsed Time: 33.05 seconds